5 citations
,
June 2017 in “BJU international” In this review, the authors highlight the occupational risks faced by pregnant urologists, such as radiation and exposure to certain medications, and emphasize the importance of avoiding specific drugs and practicing good hygiene, but note limited data on radiation risk.
1 citations
,
November 2024 in “Archives of Dermatological Research”
August 2017 in “Journal of Pharmacy Practice and Research” This study details a method for assessing the risk of modifications to pharmaceutical frame formulations by assigning a risk priority number using Failure Modes Effects Analysis, which estimates the severity and probability of changes impacting the formulation.
September 2023 in “Journal of the American Academy of Dermatology” 1 citations
,
November 2025 in “Neuro-Oncology” In this study, safusidenib erbumine was evaluated for its efficacy and safety in patients with untreated IDH1-mutated WHO grade 2 gliomas, achieving a 44.4% objective response rate and 87.9% 24-month event-free probability, but with some mild to moderate adverse effects.
April 2019 in “The Journal of urology/The journal of urology” After the FDA's 2011 warning about a potential prostate cancer risk with 5-alpha reductase inhibitors, this study observed a significant decrease in their prescriptions, notably a 49% drop among men with benign prostatic hyperplasia, while primary care providers reduced prescriptions by 60%.
July 2025 in “Jurnal Farmasi Sains dan Praktis” This study found that breast cancer patients treated with the docetaxel-doxorubicin regimen experienced various adverse drug reactions, with nausea being the most common and mainly mild in severity.
September 2023 in “Journal of the American Academy of Dermatology” Risankizumab effectively treats and maintains skin clearance in moderate-to-severe psoriasis.
November 2008 in “Cancer Prevention Research” This article reviews pivotal trials and recent findings in chemoprevention for breast, prostate, and colorectal cancers, emphasizing its potential and the importance of further research, public education, and partnerships, but reports no new results.
3 citations
,
November 2025 in “Biomimetics” This review discusses the potential of hydrogel-based interventions for radiation-induced skin injury, providing no new clinical results but highlighting their synergistic mechanisms and promise in improving treatment strategies.
December 2015 in “Vascular Pharmacology” Prasugrel is better than clopidogrel at preventing heart damage and improving blood flow in small heart vessels during heart artery procedures.
July 2023 in “Media Dermato Venereologica Indonesiana” This case study highlights that RDEB-mitis can be misdiagnosed in older adults, emphasizing the importance of accurate diagnosis as it does not require immunosuppressive treatment.
2 citations
,
October 2025 in “Frontiers in Medicine” This study identified several previously unrecognized adverse events linked to ISO, including serious conditions such as Dandy-Walker syndrome and suicidal ideation, suggesting that safety measures and drug labeling should be updated.
May 2026 in “Pharmaceuticals” This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.
January 2025 in “Dermatology Reports” This case report describes a 61-year-old Italian man with a rare, localized variant of junctional epidermolysis bullosa linked to the R795X mutation in the COL17A1 gene, highlighting the importance of precise diagnosis for effective management of rare genetic disorders.
184 citations
,
October 2007 in “Proceedings of the National Academy of Sciences of the United States of America” This study found that sulforaphane-rich broccoli sprout extracts reduced UV-induced erythema by 37.7% in humans, suggesting a protective strategy against UVR damage.
January 2002 in “映像情報メディア学会技術報告” This study found that 60% of examined prostate tumors had new somatic substitutions in the SRD5A2 gene, affecting enzyme activity and potentially influencing prostate cancer progression.
6 citations
,
June 2009 in “Journal of Clinical Oncology” This study reports that 5-alpha-reductase inhibitors do not prevent prostate cancer and merely reduce the likelihood of undergoing diagnostic biopsies, potentially misleading patients and physicians.
December 2025 in “Applied and Computational Engineering” In this study, researchers explored the potential allergenicity and harmful effects of hair dyes, noting that adverse effects such as sensitization and potential carcinogenicity are not inevitable and can vary based on individual physiological differences.
January 2026 in “Nutrición Hospitalaria” In this study, researchers identified significant signals indicating previously unrecognized risks of lipid metabolism abnormalities for several drugs, urging the need for better monitoring and label updates.
20 citations
,
August 2016 in “BMJ Open” This study found that introducing warning symbols and educational programs significantly reduced the erroneous crushing of medications in nursing homes.
9 citations
,
August 2019 in “Clinical genitourinary cancer” This study suggests that 5-alpha reductase inhibitors may reduce invasive cancer features and improve survival in men undergoing radical cystectomy for high-grade urothelial carcinoma, although further research is needed to confirm these findings.
June 2026 in “Pharmaceuticals” This study found that while 5α-reductase inhibitors like finasteride had many serious, unresolved adverse drug reactions, some were not listed in the existing product information.
January 2009 in “The Chinese Journal of Modern Applied Pharmacy” This study concluded that QSPR models effectively predict drug skin penetration, with the Potts-Guy model showing the highest predictive accuracy for the drugs tested.
28 citations
,
September 2016 in “Future oncology” In this study, a UK expert panel discussed strategies for managing common side effects of vismodegib, a hedgehog pathway inhibitor used for advanced basal cell carcinoma, concluding that adverse events like taste disturbances and muscle cramps can be effectively managed to optimize treatment duration.
February 2026 in “UiTM Institutional Repositories (Universiti Teknologi MARA)” This study found that cis-urocanic acid can engage in non-enzymatic reactions with reactive sulphur species, forming new metabolites, and suggests sulphide donors may protect against UVB-related toxicity.
9 citations
,
March 2024 in “Journal of Biomaterials Applications” This study developed dissolving microneedles using specific polymers for transdermal delivery of rizatriptan benzoate, demonstrating improved drug skin penetration and significant alleviation of migraine symptoms in vivo compared to passive diffusion, suggesting potential advantages over conventional treatment methods for acute migraine.
5-ARI therapy may help prevent prostate cancer progression.
September 2005 in “電子情報通信学会ソサイエティ大会講演論文集” This review discusses various cancer prevention strategies, summarizing established successes like tamoxifen for breast cancer and mixed outcomes of preventive trials like finasteride for prostate cancer, and reports no new results.
May 2011 in “Psychiatric News” This article provides regulatory updates, legal briefs, and industry news, reporting no new clinical findings.